Omniose
Business Services · Missouri, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4340 Duncan Ave Ste 202, St. Louis, Miss...Website
www.omniose.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Omniose
Omniose was founded in 2017 based on the pioneering glycoconjugation discoveries of the company's scientific founders Mario Feldman and Christian Harding through a scientific collaboration that characterized a new class of conjugating enzymes. The research operations were established at BioGenerator Accelerator Labs in St. Louis and the company was previously known as VaxNewMo. Omniose has been awarded grants from the US NIAID for use of the company's platform technology to develop vaccines against Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae.Explore more
Omniose Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Omniose your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Omniose
Product Launch: Get notified when Omniose launches new products
Funding: Get notified immidiatlly once Omniose has new funding data
Earning: See what the market has to say on Omniose recently announced quarterly report
Check out if Omniose is spiking on competitors!
Omniose, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Omniose has recently received funding, and reach out quickly before it becomes old news!
Click to see if Omniose had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Omniose
Compare insights from companies similar to Omniose, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Omniose is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Omniose is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Omniose.
Omniose financials insights
Gather financial insights about Omniose, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Grant
$3.6M
Omniose Tech Stack
A closer look at the technologies used by Omniose
Most Recent Scoops
Funding
Executive Move
Board of Directors
New Hire
Executive Move
Timothy Cooke has been named Chief Executive Officer. Previously, Cook served as Chief Executive Officer at NovaDigm Therapeutics.
New Hire
Executive Move
Omniose News & Media
Omniose Awarded NIH Grant of up to $3.0 Million to Develop Vaccines against Group B Streptococcus
BOSTON & ST. LOUIS--(BUSINESS WIRE)--Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today a grant award up to $3.0 million for the development of a Group B Streptococcus (GBS) vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health. Group B Streptococcus is a leading cause of invasive bacterial infections in neonates1 and older adults2 in the US and causes an estimated 90,000 iOmniose Receives $3.6M Grant from NIH
Omniose, a Boston, MA and Saint Louis, MO-based company developing polysaccharide conjugate vaccines against serious bacterial threats, received a $3.6M grant. The award came from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health. The company intends to use the funds for the development of a Klebsiella pneumoniae vaccine. Led by […] The post Omniose Receives $3.6M Grant from NIH appeared first on FinSMEs.Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae
BOSTON & ST. LOUIS--(BUSINESS WIRE)--Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, has been awarded a $3.6 million grant for the development of a Klebsiella pneumoniae vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health. Klebsiella pneumoniae is a leading cause of life-threatening sepsis in newborns1 as well as healthcare-associated infections, including pneumonia, bloodstream infec
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Omniose
Sign Up For FreeTo access detailed company insights
Omniose was founded in 2017 based on the pioneering glycoconjugation discoveries of the company's scientific founders Mario Feldman and Christian Harding through a scientific collaboration that characterized a new class of conjugating enzymes. The research operations were established at BioGenerator Accelerator Labs in St. Louis and the company was... Read More
